Evaluation of the WHO 2010 Grading and AJCC/UICC Staging Systems in Prognostic Behavior of Intestinal Neuroendocrine Tumors

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Araujo, Paula B ^a   Cheng, Sonia ^a   Mete, Ozgur ^a   Serra, Stefano ^a   Morin, Emilie ^a   Asa, Sylvia L ^a   Ezzat, Shereen ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE; FLUOROURACIL; PENTETREOTIDE; PLATINUM COMPLEX; SOMATOSTATIN DERIVATIVE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL EVALUATION; DISEASE SPECIFIC SURVIVAL; DISTANT METASTASIS; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; INTESTINAL NEUROENDOCRINE TUMOR; INTESTINE RESECTION; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PALLIATIVE THERAPY; PROGRESSION FREE SURVIVAL; SYSTEMIC THERAPY; WORLD HEALTH ORGANIZATION;

FEMALE; HUMANS; INTESTINAL NEOPLASMS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; PROGNOSIS; SOMATOSTATIN; WORLD HEALTH ORGANIZATION;

EID: 84876437261     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061538     Document Type: Article

References (31)

1. Rindi G, Arnold R, Bosman FT, Capella C, Klimstra DS, et al. (2010) Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT CF, Hruban RH, Theise N., editor. WHO classification of tumors of the digestive system. 4th ed. Lyon: International Agency for Research on Cancer. pp. 13-14.
2. Modlin IM, Lye KD, Kidd M, (2003) A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97: 934-959.
3. Bilimoria KY, Bentrem DJ, Wayne JD, Ko CY, Bennett CL, et al. (2009) Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg 249: 63-71.
4. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, et al. (2008) One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 26: 3063-3072.
5. Boudreaux JP, Klimstra DS, Hassan MM, Woltering EA, Jensen RT, et al. (2010) The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas 39: 753-766.
6. Valentino J, Evers BM, (2011) Recent advances in the diagnosis and treatment of gastrointestinal carcinoids. Adv Surg 45: 285-300.
7. Scherubl H, Jensen RT, Cadiot G, Stolzel U, Kloppel G, (2010) Neuroendocrine tumors of the small bowels are on the rise: Early aspects and management. World J Gastrointest Endosc 2: 325-334.
8. Vinik AI, Woltering EA, Warner RR, Caplin M, O'Dorisio TM, et al. (2010) NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas 39: 713-734.
9. Pape UF, Perren A, Niederle B, Gross D, Gress T, et al. (2012) ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology 95: 135-156.
10. Pavel M, Baudin E, Couvelard A, Krenning E, Oberg K, et al. (2012) ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95: 157-176.
11. Vogl TJ, Naguib NN, Zangos S, Eichler K, Hedayati A, et al. (2009) Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation. Eur J Radiol 72: 517-528.
12. Grozinsky-Glasberg S, Shimon I, Korbonits M, Grossman AB, (2008) Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. Endocrine-related cancer 15: 701-720.
13. Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, et al. (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 27: 4656-4663.
14. Fazio N, de Braud F, Delle Fave G, Oberg K, (2007) Interferon-alpha and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination? Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 18: 13-19.
15. Turner NC, Strauss SJ, Sarker D, Gillmore R, Kirkwood A, et al. (2010) Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer 102: 1106-1112.
16. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Horsch D, et al. (2011) Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378: 2005-2012.
17. Dong M, Phan AT, Yao JC, (2012) New strategies for advanced neuroendocrine tumors in the era of targeted therapy. Clin Cancer Res 18: 1830-1836.
18. Landry CS, Brock G, Scoggins CR, McMasters KM, Martin RC 2nd, (2008) A proposed staging system for small bowel carcinoid tumors based on an analysis of 6,380 patients. Am J Surg 196: 896-903; discussion 903.
19. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S, (2010) The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 39: 707-712.
20. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, et al. (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247.
21. Mete O, Asa SL, (2011) Pathological definition and clinical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation. Mod Pathol 24: 1545-1552.
22. Kloppel G, Rindi G, Perren A, Komminoth P, Klimstra DS, (2010) The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement. Virchows Archiv: an international journal of pathology 456: 595-597.
23. Cunningham JL, Grimelius L, Sundin A, Agarwal S, Janson ET, (2007) Malignant ileocaecal serotonin-producing carcinoid tumours: the presence of a solid growth pattern and/or Ki67 index above 1% identifies patients with a poorer prognosis. Acta Oncol 46: 747-756.
24. Liu E, Telem DA, Hwang J, Warner RR, Dikman A, et al. (2010) The clinical utility of Ki-67 in assessing tumor biology and aggressiveness in patients with appendiceal carcinoids. J Surg Oncol 102: 338-341.
25. Dhall D, Mertens R, Bresee C, Parakh R, Wang HL, et al. (2012) Ki-67 proliferative index predicts progression-free survival of patients with well-differentiated ileal neuroendocrine tumors. Hum Pathol 43: 489-495.
26. Bergsland EK, (2013) The evolving landscape of neuroendocrine tumors. Semin Oncol 40: 4-22.
27. Bushnell DL, Baum RP, (2011) Standard imaging techniques for neuroendocrine tumors. Endocrinol Metab Clin North Am 40: 153-162, ix.
28. Asnacios A, Courbon F, Rochaix P, Bauvin E, Cances-Lauwers V, et al. (2008) Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 26: 963-970.
29. Theodoropoulou M, Zhang J, Laupheimer S, Paez-Pereda M, Erneux C, et al. (2006) Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Res 66: 1576-1582.
30. Anthony L, Vinik AI, (2011) Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period. Pancreas 40: 987-994.
31. Toumpanakis C, Garland J, Marelli L, Srirajaskanthan R, Soh J, et al. (2009) Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR. Aliment Pharmacol Ther 30: 733-740.